fumonisin-b1 and Diabetes-Mellitus--Type-2

fumonisin-b1 has been researched along with Diabetes-Mellitus--Type-2* in 2 studies

Other Studies

2 other study(ies) available for fumonisin-b1 and Diabetes-Mellitus--Type-2

ArticleYear
Obesity promotes fumonisin B1 hepatotoxicity.
    The Science of the total environment, 2023, Sep-15, Volume: 891

    Obesity, which is a worldwide public health issue, is associated with chronic inflammation that contribute to long-term complications, including insulin resistance, type 2 diabetes and non-alcoholic fatty liver disease. We hypothesized that obesity may also influence the sensitivity to food contaminants, such as fumonisin B1 (FB1), a mycotoxin produced mainly by the Fusarium verticillioides. FB1, a common contaminant of corn, is the most abundant and best characterized member of the fumonisins family. We investigated whether diet-induced obesity could modulate the sensitivity to oral FB1 exposure, with emphasis on gut health and hepatotoxicity. Thus, metabolic effects of FB1 were assessed in obese and non-obese male C57BL/6J mice. Mice received a high-fat diet (HFD) or normal chow diet (CHOW) for 15 weeks. Then, during the last three weeks, mice were exposed to these diets in combination or not with FB1 (10 mg/kg body weight/day) through drinking water. As expected, HFD feeding induced significant body weight gain, increased fasting glycemia, and hepatic steatosis. Combined exposure to HFD and FB1 resulted in body weight loss and a decrease in fasting blood glucose level. This co-exposition also induces gut dysbiosis, an increase in plasma FB1 level, a decrease in liver weight and hepatic steatosis. Moreover, plasma transaminase levels were significantly increased and associated with liver inflammation in HFD/FB1-treated mice. Liver gene expression analysis revealed that the combined exposure to HFD and FB1 was associated with reduced expression of genes involved in lipogenesis and increased expression of immune response and cell cycle-associated genes. These results suggest that, in the context of obesity, FB1 exposure promotes gut dysbiosis and severe liver inflammation. To our knowledge, this study provides the first example of obesity-induced hepatitis in response to a food contaminant.

    Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Dysbiosis; Fumonisins; Inflammation; Liver; Male; Mice; Mice, Inbred C57BL; Obesity

2023
Selective lack of the C16:0 fatty acid isoform of sulfatide in pancreas of type II diabetic animal models.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2003, Volume: 111, Issue:9

    Sulfatide (3'-sulfogalactosyl-ceramide) is a glycosphingolipid mainly located in the nervous system, but has also been found in the islets of Langerhans. Previous studies have suggested that sulfatide is involved in insulin processing and secretion. In this study, sulfatide expression and metabolism in pancreas and isolated islets of the type II diabetes models, ob/ob- and db/db mouse, was investigated using TLC-ELISA, metabolic labelling and electron microscopy. As in non-diabetic Lewis rat and human pancreas, sulfatide was located in secretory granules of the beta cells. However, the type II diabetic animal models and their background strains had an altered sulfatide expression, involving the lack of the C16:0 sulfatide fatty acid isoform, compared to non-diabetic Lewis rat, BALB/c mouse and human pancreatic tissue, in which the two dominating pancreatic sulfatide isoforms C16:0 and C24:0 are expressed. Correspondingly, in isolated ob/ob islets, sulfatide synthesis excluded the production of C16:0 sulfatide. Insulin administration to ob/ob mouse, which lowers beta cell activity, resulted in significantly increased sulfatide expression in pancreas (p=0.0003), but still no expression of the C16:0 sulfatide isoform. In vitro, the C16:0 sulfatide was shown to be the isomer involved in the preservation of insulin crystals. Thus, it is hypothesized that the selection of sulfatide isomers in pancreas might be a genetic factor contributing to disease development in type II diabetic animal models.

    Topics: Animals; Brefeldin A; Chloroquine; Chromatography, Thin Layer; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Fatty Acids; Fumonisins; Galactosylceramides; Humans; Islets of Langerhans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Obese; Microscopy, Electron; Protein Isoforms; Protein Synthesis Inhibitors; Rats; Rats, Inbred Lew; Spectrometry, Mass, Electrospray Ionization; Sulfoglycosphingolipids

2003